Prices are updated after-hours


Sort by: gain open | gain high | gain close | publishing date

symbols : ALNY    save search

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2022-01-21 (Crawled : 13:00) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -10.41% H: 0.0% C: 0.0%

positive results phase 3
18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at SFNP
Published: 2022-01-21 (Crawled : 13:00) - alnylam.com
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -10.41% H: 0.0% C: 0.0%

results phase 3
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: -1.41% H: 0.0% C: 0.0%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -2.91% H: 2.06% C: -1.88%
STOK | $18.14 | twitter stocktwits trandingview |
Health Technology
| | O: -1.31% H: 2.13% C: -3.48%

era technology therapeutics
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -2.0% H: 0.0% C: 0.0%

rare ces era technology therapeutics disease
At 17.42% CAGR, Oligonucleotide Synthesis Market Size is Expected to Reach USD 22584.1 Million in 2028, says Brandessence Market Research
Published: 2022-01-17 (Crawled : 13:30) - prnewswire.com
SRPT | $64.59 | twitter stocktwits trandingview |
Health Technology

DHR | $282.96 | twitter stocktwits trandingview |
Health Technology

ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology

BIIB | News | $225.91 | twitter stocktwits trandingview |
Health Technology

IONS | $30.01 | twitter stocktwits trandingview |
Health Technology

TWST | $56.99 | twitter stocktwits trandingview |
Health Technology

ce mark leo research
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
Published: 2022-01-14 (Crawled : 12:30) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 1.47% H: 0.0% C: 0.0%

results phase 3
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.31% H: 0.0% C: 0.0%


Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -3.19% H: 0.0% C: -3.32%

novartis ces announces collaboration era liver therapy collaboration
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 0.34% H: 0.0% C: 0.0%

ces
Alnylam to Webcast Presentation at 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-03 (Crawled : 13:00) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 0.96% H: 0.0% C: 0.0%

health thc conference presentation j.p. morgan healthcare conference
Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C
Published: 2021-12-22 (Crawled : 23:00) - biospace.com/
NVS | News | $88.91 | twitter stocktwits trandingview |
Health Technology
| | O: -0.55% H: 0.99% C: 0.92%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -5.24% H: 2.44% C: -0.93%

leqvio fda fda approval era approval
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.59% H: 1.12% C: 0.93%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -5.24% H: 2.44% C: -0.93%

alzheimer treatment application era disease
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.59% H: 0.18% C: -0.2%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 6.14% H: 2.21% C: 1.59%

treatment application era
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement of the Alnylam Pharmaceuticals, Inc. Securities Litigation
Published: 2021-12-17 (Crawled : 15:30) - prnewswire.com
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%

als ces
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.51% H: 0.0% C: 0.0%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 6.02% H: 2.03% C: -0.29%
SNYNF | News 3 d | $105.0 | twitter stocktwits trandingview |
Health Technology
| | O: -3.62% H: 0.0% C: -0.56%

oxlumo treatment europe application expansion drug food
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 6.02% H: 2.03% C: -0.29%

phase 1 results
New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 6.02% H: 2.03% C: -0.29%

givlaari results
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News 3 d | $105.0 | twitter stocktwits trandingview |
Health Technology
| | O: 3.01% H: 0.28% C: -2.39%
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: -0.42% H: 0.0% C: 0.0%
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 2.8% H: 0.0% C: 0.0%

results phase 3
ILLUMINATE-B Phase 3 Results of OXLUMO® (lumasiran) Published in Genetics in Medicine
Published: 2021-12-09 (Crawled : 15:30) - alnylam.com
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: 0.29% H: 0.31% C: -2.8%

oxlumo genetic results phase 3
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2021-11-19 (Crawled : 12:30) - biospace.com/
ALNY | News | $138.31 | twitter stocktwits trandingview |
Health Technology
| | O: -2.38% H: 4.35% C: 3.59%


Your saved searches


Save your searches and get alerts when important news are released.

Mentioned Today
COTY | News | $8.64 | twitter stocktwits trandingview |
Consumer Non-Durables

DXR | News | $11.16 | twitter stocktwits trandingview |
Health Technology

FCFS | News | $73.31 | twitter stocktwits trandingview |
Finance

INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

KRP | News | $14.73 | twitter stocktwits trandingview |
Miscellaneous

LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology

OVLY | News | $17.6 | twitter stocktwits trandingview |
Finance